|
Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company - Expects to announce initial faridoxorubicin phase 1b data in the salivary gland cancer indication next week Wednesday. Back in October, Avacta had said faridoxorubicin showed positive tolerability and safety in patents across both the every three weeks and every two weeks dosing regiments. Faridoxorubicin is a form of doxorubicin designed to reduce the systemic side effects of conventional chemotherapy and concentrate the active payload in the tumour microenvironment. Doxorubicin is a chemotherapy drug used to treat cancer. Current stock price: 80.70 pence, up 2.2% on Monday morning in London 12-month change: up 78% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
